Granisetron
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Granisetron
- Granisetron: From Chemotherapy-Induced Nausea and Vomiting to Manic Bipolar Affective Disorder
Granisetron: From Chemotherapy-Induced Nausea and Vomiting to Manic Bipolar Affective Disorder
One-Sentence Summary
Granisetron is a selective 5-HT3 receptor antagonist established for preventing chemotherapy- and radiotherapy-induced nausea and vomiting. The TxGNN model predicts it may also be effective for Manic Bipolar Affective Disorder, but this direction is currently supported by 0 clinical trials and 0 publications — the signal rests entirely on a mechanistic hypothesis, not on observed clinical data.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chemotherapy-/radiotherapy-induced nausea and vomiting (general pharmacological knowledge for granisetron; no jurisdiction-specific license text is available because the drug is not marketed in the evaluated jurisdiction) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, sourced mechanism-of-action data for granisetron is not available in this evidence pack (flagged as a High-severity data gap). What is available comes from the model’s own repurposing rationale, which identifies granisetron as a 5-HT3 (serotonin) receptor antagonist. The rationale proposes that 5-HT3 blockade could theoretically modulate central serotonin–dopamine crosstalk implicated in mood circuitry, drawing an analogy to exploratory adjunctive use of a related 5-HT3 antagonist (ondansetron) in mania. Critically, the evidence pack itself flags this as an extrapolation: granisetron has no direct data in bipolar disorder, and the link is described as a “mechanistic extension, lacking direct evidence.”
This same 5-HT3-antagonism mechanism appears repeatedly across the ten TxGNN predictions in this pack, but the model’s own scoring treats it very differently depending on plausibility. For manic bipolar affective disorder, Tourette syndrome, and trichotillomania, the recommendation is “Research Question” — these are conditions with known serotonergic/dopaminergic involvement, so a central 5-HT3 mechanism is at least biologically conceivable. For conjunctivitis, allergic/cold urticaria, angioedema, bronchitis, and nephrogenic SIAD, the recommendation is “Hold” — these conditions have no plausible connection to 5-HT3 antagonism, and several (urticaria, angioedema) are actually known adverse effects of granisetron, suggesting the model may be picking up an adverse-event co-occurrence signal in the knowledge graph rather than a genuine therapeutic association.
In short, the mania prediction is the most mechanistically defensible of the ten candidates, but it remains a hypothesis generated purely from graph-based inference, with no supporting trial or literature evidence to date.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Granisetron currently has no marketing authorization on record in the evaluated jurisdiction (market status: Not Marketed; 0 licenses). No product/dosage-form/indication data is available to tabulate.
Safety Considerations
Please refer to the SmPC for safety information. (Warnings, contraindications, and drug–drug interaction data for granisetron were not retrievable in this evidence pack — this is logged as a Blocking data gap that must be resolved before any safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (manic bipolar affective disorder) is supported only by a model score and an unvalidated mechanistic hypothesis — there are zero clinical trials and zero publications, placing this at the lowest evidence tier (L5). Compounding this, a Blocking data gap on TFDA warning/contraindication information means a basic safety assessment (S1) cannot even be initiated, and granisetron holds no marketing authorization in the evaluated jurisdiction.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings and contraindications) to resolve the Blocking data gap and enable a safety pre-screen
- Verified mechanism-of-action data via DrugBank API to properly assess the biological plausibility of the serotonin–mania link
- Preclinical or mechanistic studies specifically examining 5-HT3 antagonism in mood/impulse-control disorders (bipolar mania, Tourette syndrome, trichotillomania), since current support is inferred by analogy to other 5-HT3 antagonists rather than granisetron-specific data
- Confirmation of current market/authorization status for granisetron in the target jurisdiction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.